by MM360 Staff | Dec 12, 2025 | Publications
Diagnostics (Basel). 2025 Nov 21;15(23):2942. doi: 10.3390/diagnostics15232942. ABSTRACT After publication, the authors identified several errors in the manuscript, including inconsistencies between the manuscript’s reported results and the corresponding...
by MM360 Staff | Dec 12, 2025 | Publications
Cancers (Basel). 2025 Nov 21;17(23):3730. doi: 10.3390/cancers17233730. ABSTRACT BACKGROUND: Despite recent advances in the treatment of multiple myeloma (MM), the disease remains incurable. Agents targeting the programmed death-1 (PD-1) axis have become key...
by Marisa Wexler, MS | Dec 11, 2025 | Myeloma News
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH mutations. That’s according to newly published results from a Phase...
by MM360 Staff | Dec 11, 2025 | Publications
Blood Cell Ther. 2025 Nov 25;8(4):301-310. doi: 10.31547/bct-2025-008. eCollection 2025 Nov 25. ABSTRACT BACKGROUND: The optimal conditioning dose of melphalan for autologous hematopoietic stem cell transplantation (AHSCT) in multiple myeloma remains a subject of...
by Marisa Wexler, MS | Dec 10, 2025 | Myeloma News
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The DESTINY-Ovarian01 trial (NCT06819007) aims to enroll 582 women with advanced ovarian cancer whose tumors...
